Skip To Main Content

Belvarafenib (pan-RAF inhibitor)

(RG6185)

Melanoma

Phase I

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma

NCT04835805

Solid Tumor

Phase I

HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

NCT03284502